Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy

Small-animal tumor models are essential for developing translational therapeutic strategies in oncology research, with imaging having an increasingly important role. Magnetic resonance imaging (MRI) offers tumor localization, volumetric measurement, and the potential for advanced physiologic imaging...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah C. Jost, Lynne Collins, Sarah Travers, David Piwnica-Worms, Joel R. Garbow
Format: Article
Language:English
Published: SAGE Publishing 2009-09-01
Series:Molecular Imaging
Online Access:https://doi.org/10.2310/7290.2009.00023
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841564124642803712
author Sarah C. Jost
Lynne Collins
Sarah Travers
David Piwnica-Worms
Joel R. Garbow
author_facet Sarah C. Jost
Lynne Collins
Sarah Travers
David Piwnica-Worms
Joel R. Garbow
author_sort Sarah C. Jost
collection DOAJ
description Small-animal tumor models are essential for developing translational therapeutic strategies in oncology research, with imaging having an increasingly important role. Magnetic resonance imaging (MRI) offers tumor localization, volumetric measurement, and the potential for advanced physiologic imaging but is less well suited to high-throughput studies and has limited capacity to assess early tumor growth. Bioluminescence imaging (BLI) identifies tumors early, monitors tumor growth, and efficiently measures response to therapeutic intervention. Generally, BLI signals have been found to correlate well with magnetic resonance measurements of tumor volume. However, in our studies of small-animal models of malignant brain tumors, we have observed specific instances in which BLI data do not correlate with corresponding MRIs. These observations led us to hypothesize that use of BLI and MRI together, rather than in isolation, would allow more effective and efficient measures of tumor growth in preclinical studies. Herein we describe combining BLI and MRI studies to characterize tumor growth in a mouse model of glioblastoma. The results led us to suggest a cost-effective, multimodality strategy for selecting cohorts of animals with similar tumor growth patterns that improves the accuracy of longitudinal in vivo measurements of tumor growth and treatment response in preclinical therapeutic studies.
format Article
id doaj-art-bd03361bd3db41218e56a51927ecf709
institution Kabale University
issn 1536-0121
language English
publishDate 2009-09-01
publisher SAGE Publishing
record_format Article
series Molecular Imaging
spelling doaj-art-bd03361bd3db41218e56a51927ecf7092025-01-02T23:12:06ZengSAGE PublishingMolecular Imaging1536-01212009-09-01810.2310/7290.2009.0002310.2310_7290.2009.00023Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging StrategySarah C. JostLynne CollinsSarah TraversDavid Piwnica-WormsJoel R. GarbowSmall-animal tumor models are essential for developing translational therapeutic strategies in oncology research, with imaging having an increasingly important role. Magnetic resonance imaging (MRI) offers tumor localization, volumetric measurement, and the potential for advanced physiologic imaging but is less well suited to high-throughput studies and has limited capacity to assess early tumor growth. Bioluminescence imaging (BLI) identifies tumors early, monitors tumor growth, and efficiently measures response to therapeutic intervention. Generally, BLI signals have been found to correlate well with magnetic resonance measurements of tumor volume. However, in our studies of small-animal models of malignant brain tumors, we have observed specific instances in which BLI data do not correlate with corresponding MRIs. These observations led us to hypothesize that use of BLI and MRI together, rather than in isolation, would allow more effective and efficient measures of tumor growth in preclinical studies. Herein we describe combining BLI and MRI studies to characterize tumor growth in a mouse model of glioblastoma. The results led us to suggest a cost-effective, multimodality strategy for selecting cohorts of animals with similar tumor growth patterns that improves the accuracy of longitudinal in vivo measurements of tumor growth and treatment response in preclinical therapeutic studies.https://doi.org/10.2310/7290.2009.00023
spellingShingle Sarah C. Jost
Lynne Collins
Sarah Travers
David Piwnica-Worms
Joel R. Garbow
Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy
Molecular Imaging
title Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy
title_full Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy
title_fullStr Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy
title_full_unstemmed Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy
title_short Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy
title_sort measuring brain tumor growth combined bioluminescence imaging magnetic resonance imaging strategy
url https://doi.org/10.2310/7290.2009.00023
work_keys_str_mv AT sarahcjost measuringbraintumorgrowthcombinedbioluminescenceimagingmagneticresonanceimagingstrategy
AT lynnecollins measuringbraintumorgrowthcombinedbioluminescenceimagingmagneticresonanceimagingstrategy
AT sarahtravers measuringbraintumorgrowthcombinedbioluminescenceimagingmagneticresonanceimagingstrategy
AT davidpiwnicaworms measuringbraintumorgrowthcombinedbioluminescenceimagingmagneticresonanceimagingstrategy
AT joelrgarbow measuringbraintumorgrowthcombinedbioluminescenceimagingmagneticresonanceimagingstrategy